TABLE 1.

Patients' demographic and clinical data

Patient no.	Age (yr)/gender	Diagnosisa	Pathogen(s)	C-reactive protein concn (mg/dl)	Soft-tissue destruction	pOPb	Concomitant disease(s) or factorc
1d	48/male	K	MRSE, Enterococcus faecalis, Staphylococcus haemolyticus	1.8	Fistula	8	HBP, smoking
2	69/male	H	MRSA	5.0	Fistula	4	HBP, COLD, CHD, smoking
3	64/male	H	MRSA	0.6	Defect	5	ALC, PAVD, CHD, smoking
4	58/female	K	MRSE, Enterococcus faecalis, Staphylococcus haemolyticus	0.7	Defect	4	HBP, CHD, smoking
5e	82/female	H	MRSE, Pseudomonas aeruginosa	9.9	Defect	4	DM, HBP, CHD, PAVD
6	76/female	H	MRSA, MSSAf	0.6	Fistula	4	DM, HBP, CHD
7	69/female	H	MRSA	1.5	Fistula	3	DM, HBP, CHD
8	78/female	H	MRSE	3.5	Fistula	3	HBP, CHD
9d	69/male	O	MRSE, Enterococcus faecalis	0.7	Fistula	2	HBP, CHD
10	52/male	O	MRSA	27.5	Fistula	8	Smoking
11	55/male	O	MRSA	0.6	Fistula	4	COLD, HBP, CHD, PAVD
12d	51/male	O	MRSA	20.2	Fistula	6	Smoking
13	69/female	H	MRSE	1.5	Fistula	3	COLD, HBP, CHD, PAVD

^aK, knee endoprosthesis; H, hip endoprosthesis; O, exacerbated osteomyelitis in the presence of orthopedic implant.

^bpOP, previous operations.

^cHBP, high blood pressure; COLD, chronic obstructive lung disease; CHD, coronary heart disease; ALC, alcoholism; PAVD, peripheral arterial vessel disease; DM, diabetes mellitus.

^dTreated with linezolid for 24 h before surgery.

^eAdditionally treated with imipenem-cilastatin.

^fMSSA, methicillin-sensitive Staphylococcus aureus.